Neurotrope BioScience

📖 Wiki Page

company691 wordssynced 2026-04-02

Overview

flowchart TD companies_neurotrope["Neurotrope BioScience"] style companies_neurotrope fill:#4fc3f7,stroke:#333,color:#000 companies_neurotrope_0["Funding"] companies_neurotrope -->|"includes"| companies_neurotrope_0 style companies_neurotrope_0 fill:#81c784,stroke:#333,color:#000 companies_neurotrope_1["Company Information"] companies_neurotrope -->|"includes"| companies_neurotrope_1 style companies_neurotrope_1 fill:#ef5350,stroke:#333,color:#000 companies_neurotrope_2["History and Milestones"] companies_neurotrope -->|"includes"| companies_neurotrope_2 style companies_neurotrope_2 fill:#ffd54f,stroke:#333,color:#000 companies_neurotrope_3["Technology Platform"] companies_neurotrope -->|"includes"| companies_neurotrope_3 style companies_neurotrope_3 fill:#ce93d8,stroke:#333,color:#000 companies_neurotrope_4["Protein Kinase C PKC Modulation"] companies_neurotrope -->|"includes"| companies_neurotrope_4 style companies_neurotrope_4 fill:#4fc3f7,stroke:#333,color:#000 companies_neurotrope_5["Bryostatin Chemistry"] companies_neurotrope -->|"includes"| companies_neurotrope_5 style companies_neurotrope_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Neurotrope BioScience, Inc. (NASDAQ: NTRP) is a clinical-stage biopharmaceutical company headquartered in New York, NY, focused on developing novel therapies for Alzheimer's disease (AD) and other neurodegenerative disorders. The company is known for its development of bryostatin, a protein kinase C (PKC) modulator, as a potential treatment for Alzheimer's disease that aims to promote synaptic repair and neuroprotection["@neurotrope"].

Funding

IPO: 2017 (NASDAQ: NTRP)

History and Milestones

Neurotrope was founded in 2012 with a focus on developing PKC-targeted therapies for neurological disorders. The company went public in 2014 on NASDAQ[@neurotrope].

Key milestones:

2012: Company founded
2014: Initial public offering (NASDAQ: NTRP)
2015: Phase 2 trial initiation for bryostatin in AD
2020: Continued clinical development despite challenges
2022: Strategic pipeline review and future planning

Technology Platform

Protein Kinase C (PKC) Modulation

Neurotrope's platform centers on protein kinase C (PKC) epsilon (PKCε) activation[@alkon2007]:

PKC Function: PKC enzymes are critical for synaptic plasticity, memory formation, and neuronal survival
PKC in AD: PKC signaling is impaired in Alzheimer's disease, contributing to synaptic loss
Therapeutic Approach: PKC epsilon activation promotes synaptic repair and protects against [amyloid-beta](/proteins/amyloid-beta) toxicity

Bryostatin Chemistry

Bryostatin is a macrocyclic lactone:

Source: Originally isolated from the marine bryozoan Bugula neritina
Structure: 26-membered macrolide with multiple lactone rings
Properties: High molecular weight, complex structure, challenging synthesis

Pipeline

Bryostatin (Bryo 1/2)

| Attribute | Details |
|-----------|---------|
| Indication | Alzheimer's Disease |
| Mechanism | PKC epsilon activator |
| Stage | Phase 2 |
| Route | Intravenous infusion |
| Status | Clinical development |

Potential Benefits:

Promotes synaptic repair and formation
Enhances memory and cognitive function
Reduces amyloid-beta toxicity
Neuroprotective effects

Preclinical Programs

| Program | Indication | Stage |
|---------|------------|-------|
| PKC modulators | Various CNS disorders | Preclinical |
| Novel analogs | AD, PD | Discovery |

Clinical Development

Phase 2 Trials

Neurotrope has conducted multiple Phase 2 clinical trials evaluating bryostatin in Alzheimer's disease patients[@alkon2007]:

Trial Design:

Randomized, double-blind, placebo-controlled
Patients with mild-to-moderate AD
Primary endpoints: cognitive function (ADAS-Cog), safety
Secondary endpoints: synaptic biomarkers, functional measures

Challenges:

Complex intravenous administration
Dose optimization required
Variable patient responses

Mechanism in Alzheimer's Disease

Bryostatin's potential benefits in AD include[@alkon2007]:

Synaptic Repair: PKCε activation promotes formation of new synaptic connections

Amyloid Protection: Reduces toxicity of amyloid-beta oligomers

[Tau](/proteins/tau) Phosphorylation: Modulates tau pathology through PKC pathways

Neuroinflammation: Anti-inflammatory effects through PKC modulation

Scientific Rationale

PKC and Memory

Protein kinase C is essential for memory formation:

[Long-term Potentiation](/mechanisms/long-term-potentiation) (LTP): PKC activity is required for synaptic strengthening
Memory Consolidation: PKC signaling during memory encoding
Synaptic Plasticity: PKC modulates receptor trafficking and ion channel function

Preclinical Evidence

Animal studies show bryostatin:

Improves performance in memory tasks
Increases synaptic density in hippocampal regions
Reduces amyloid plaque burden
Protects against excitotoxicity

Competitive Landscape

Neurotrope competes in the AD therapeutic space:

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Biogen/Lecanemab | Amyloid clearance | Antibody | Approved |
| Eli Lilly | [Donanemab](/entities/donanemab) | Amyloid clearance | Approved |
| Roche | Gantenerumab | Amyloid clearance | Phase 3 |
| Neurotrope | Bryostatin | PKC activator | Phase 2 |
| Cortexyme | COR388 | Gingipain inhibitor | Phase 2/3 |

Challenges and Risks

Administration: IV infusions vs. oral drugs
Competition: Successful amyloid-targeting therapies
Efficacy: Demonstrating clinical benefit
Manufacturing: Complex bryostatin synthesis
[Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
[Protein Kinase C Signaling](/mechanisms/protein-kinase-c-signaling)
[Synaptic Plasticity](/mechanisms/synaptic-plasticity)
[Amyloid-Beta Hypothesis](/genes/th)

External Links

[Neurotrope BioScience Website](https://www.neurotrope.com)
[ClinicalTrials.gov - Neurotrope](https://clinicaltrials.gov/search?spons=Neurotrope)
[PubMed - Bryostatin Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=bryostatin+Alzheimer)

References

Unknown, Neurotrope BioScience, Inc. Corporate information and pipeline (n.d.)

[Alkon DL, Sun MK, Nelson TJ, PKC signaling deficits in Alzheimer's disease and therapeutic interventions (2007)](https://pubmed.ncbi.nlm.nih.gov/17936810/)

📖 View canonical wiki page →